Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TALS

Talaris Therapeutics (TALS) Stock Price, News & Analysis

Talaris Therapeutics logo

About Talaris Therapeutics Stock (NASDAQ:TALS)

Advanced Chart

Key Stats

Today's Range
$26.31
$30.59
50-Day Range
$12.36
$28.36
52-Week Range
$0.89
$27.95
Volume
1.03 million shs
Average Volume
386,531 shs
Market Capitalization
$1.29 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive TALS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

TALS Stock News Headlines

Tourmaline Bio, Inc. (TRML)
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.tc pixel
Longitude Venture Partners III, L.P.'s Net Worth
See More Headlines

TALS Stock Analysis - Frequently Asked Questions

Talaris Therapeutics, Inc. (NASDAQ:TALS) announced its quarterly earnings data on Friday, November, 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.35) by $0.03.

Talaris Therapeutics (TALS) raised $150 million in an initial public offering on Friday, May 7th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities acted as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Talaris Therapeutics investors own include Graphite Bio (GRPH), Vaccitech (VACC), Achilles Therapeutics (ACHL), Allogene Therapeutics (ALLO), Cytec Industries (CYT), Immunocore (IMCR) and Century Therapeutics (IPSC).

Company Calendar

Last Earnings
11/12/2021
Today
9/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TALS
CIK
1827506
Fax
N/A
Employees
84
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($1.79)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$73.89 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-39.93%
Return on Assets
-37.37%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
15.41
Quick Ratio
15.41

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.33 per share
Price / Book
6.97

Miscellaneous

Outstanding Shares
42,764,000
Free Float
35,708,000
Market Cap
$1.29 billion
Optionable
Not Optionable
Beta
2.18

Social Links

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:TALS) was last updated on 9/9/2025 by MarketBeat.com Staff
From Our Partners